Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 07:59 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to...
September 17, 2025 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for...
December 10, 2020 08:43 ET | Source: Trevena Inc.

Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting

-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
February 19, 2020 08:37 ET | Source: Aptinyx Inc.

Aptinyx to Present at Upcoming Investor Conferences

EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
January 14, 2020 16:01 ET | Source: Aptinyx Inc.

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
December 12, 2019 07:07 ET | Source: Aptinyx Inc.

Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
September 30, 2019 07:03 ET | Source: Aptinyx Inc.

Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
September 26, 2019 08:07 ET | Source: Aptinyx Inc.

Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925

EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
January 15, 2013 09:30 ET | Source: NanoInk

Genetimes Technology Named as NanoInk's New Distributor in China

CHICAGO, IL--(Marketwire - Jan 15, 2013) - NanoInk's NanoFabrication Systems Division is pleased to announce that it has reached a non-exclusive agreement with Genetimes Technology Inc. to serve as...
September 24, 2012 09:30 ET | Source: NanoProfessor

Southern Connecticut State University Expands Leadership in Nanoscience Education With NanoProfessor Program

SKOKIE, IL--(Marketwire - Sep 24, 2012) - NanoProfessor®, the global leader in hands-on undergraduate nanotechnology education, announced today that Southern Connecticut State University...